Nuveen Asset Management, LLC Unity Biotechnology, Inc. Transaction History

Nuveen Asset Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$4.15 - $6.3 $566,217 - $859,559	-136,438 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$5.51 - $9.42 $132,058 - $225,769	23,967 Added 21.31%	136,438 $819,000
Q4 2020 Feb 16, 2021	BUY	$3.42 - $6.36 $12,041 - $22,393	3,521 Added 3.23%	112,471 $589,000
Q3 2020 Nov 16, 2020	SELL	$2.94 - $12.43 $146,794 - $620,629	-49,930 Reduced 31.43%	108,950 $1.35 Million
Q2 2020 Aug 14, 2020	BUY	$5.28 - $9.67 $263,630 - $482,823	49,930 Added 45.83%	158,880 $1.38 Million
Q1 2020 May 14, 2020	BUY	$5.0 - $7.6 $56,810 - $86,351	11,362 Added 11.64%	108,950 $631,000
Q4 2019 Feb 14, 2020	SELL	$5.99 - $8.38 $5,013 - $7,014	-837 Reduced 0.85%	97,588 $703,000
Q3 2019 Nov 14, 2019	SELL	$5.62 - $9.63 $27,099 - $46,435	-4,822 Reduced 4.67%	98,425 $601,000
Q2 2019 Aug 15, 2019	BUY	$7.59 - $10.21 $783,644 - $1.05 Million	103,247 New	103,247 $981,000

4.41M

Ticker UBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,036,200
Market Cap $16.1M
Description
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular d...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.